Food Recalls, Updates March 14: H-E-B Dip, Chocolate Nut's Risk Level Set
A recalled spinach artichoke dip is a Class II risk, and updates have been issued for the recall of chocolate nut and wafer ...
PharmExec4d
FDA’s New Accelerated Approval Draft Guidance
The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated ...
dvm3601d
FDA conditionally approves first drug for feline subclinical hypertrophic cardiomyopathy
Sirolimus, the active ingredient in Felycin-CA1, at a higher dose is used as an immunosuppressant in human patients receiving ...
Endpoints News3d
FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts
Trump admin's FDA medical product review units remain protected from cuts, while Marty Makary awaits confirmation as ...
Ophthalmology Times4d
FDA accepts new drug application for low-dose atropine from Sydnexis
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Endpoints News5d
Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer
The FDA told staff on Monday that reviewers of medical products and inspectors of manufacturing facilities cannot take the ...
The American Journal of Managed Care2d
Uniform Global Standards, Processes Could Accelerate CGT Approvals, Access
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
Managed Healthcare Executive3d
FDA Approves First Generics of Xarelto
Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...
Targeted Oncology1d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
STAT4d
Pharmalittle: We’re reading about Lilly and Roche weight loss drugs, FDA and compounders, and more
Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
PharmExec3d
FDA Fast Track: Accelerating AlloNK's Development
Fred Aslan, MD, CEO, Artiva Biotherapeutics, explains what the FDA Fast Track designation for AlloNK in autoimmune diseases means for the acceleration of its development and potential approval of the ...